Articles tagged with Breast Cancer
Tamoxifen therapy for 5 years improves survival by about a third in women with hormone-sensitive breast cancer, according to an analysis of over 20,000 patients. The treatment reduces the risk of breast cancer recurrence and death in ER-positive disease, regardless of chemotherapy use.
A large UC Davis study analyzed 1.6 million mammograms and found that computer-aided detection (CAD) technology is not effective in finding breast tumors, leading to increased false-positive results and unnecessary recalls for further testing.
Scientists identify two genetic sequences that control how a breast cancer gene responds to estrogen, leading to tamoxifen resistance. The discovery may help guide the search for new therapeutic targets in breast cancer.
A study found that computer-aided detection (CAD) software used in analyzing three out of four mammograms does not improve detection rates or cancer outcomes. CAD was associated with more false positives, but did not detect smaller or less aggressive cancers.
A new study published in Journal of the American Medical Association found that removing lymph nodes due to microscopic cancer cells has no impact on survival outcomes for women with early-stage breast cancer. The study, conducted by Cedars-Sinai Medical Center, challenged the common approach to treating early-stage breast cancer.
Scientists have developed a novel protein called HER2-Affitoxin that targets HER2-positive cancer cells without interfering with the signaling pathway. The protein has shown promising results in killing tumor cells and is warranting clinical trials.
High-dose vitamin D significantly reduces musculoskeletal pain and improves quality of life for breast cancer patients on aromatase inhibitors. The study found that high-dose vitamin D may also help maintain bone density, providing a potential tool to enhance treatment tolerability.
A study found that many physicians do not follow guidelines for breast and ovarian cancer counseling and testing, affecting high-risk women who may miss out on life-saving interventions. Physicians were more likely to follow guidelines when accurately estimating patients' ovarian cancer risks.
Research found that taller individuals are at higher risk of various cancers, including breast, ovary, and bowel cancers. The study suggests that increases in population height may explain changes in cancer incidence over time.
A new drug targeting the PI3K gene has shown significant shrinkage of tumors in two patients with advanced breast and cervical cancers. The drug, GDC-0941, is being tested in an early phase I study conducted by TGen and Virginia G. Piper Cancer Center.
Researchers found that temporarily suppressing ovarian function with triptorelin reduced the occurrence of early menopause induced by chemotherapy among premenopausal women with breast cancer. The treatment resulted in a 17% lower rate of early menopause compared to chemotherapy alone.
Researchers at Whitehead Institute have identified a protein called phosphoglycerate dehydrogenase (PHGDH) that is crucial for the growth of estrogen receptor-negative breast cancer cells. PHGDH is overexpressed in approximately 70% of ER-negative breast cancer patients, making it a promising target for drug development.
Researchers discovered a new class of anti-cancer agent, BH3 mimetics, that target Bcl-2 proteins in cancer cells. Combining these agents with chemotherapy shows improved tumour response and survival rates for aggressive breast cancers.
A study published in Clinical Cancer Research found that trastuzumab, chemotherapy, and surgery significantly improved overall survival in HER2-positive breast and brain cancer patients. Treatment with these therapies led to improved survival rates of up to 20 months for those with central nervous system metastases.
Scientists have developed a tiny fiber-optic biosensor to detect elevated PSA levels in cases of breast cancer. The biosensor's sensitivity and specificity are comparable to those found in current screening methods for breast cancer.
A study found that changes in family history of cancer can significantly alter screening recommendations, particularly for colorectal, breast, and prostate cancers. For patients aged 30-50, the risk of increased cancer risk more than tripled for colorectal cancer and increased by 60% for breast cancer.
Research found substantial changes in cancer family history between ages 30-50, leading to recommendations for earlier or more intense screening. Updates to family history should occur every 5-10 years to inform risk assessments and screening guidelines.
The World Health Organization has stated that alcohol is carcinogenic in both animals and humans. Several studies have linked alcohol consumption to an increased risk of cancers in the mouth, throat, esophagus, liver, colon-rectum, and breast cancers. New international guidelines are needed to address this issue.
Research published in BMJ Open found a strong association between contact allergies and reduced rates of breast, non-melanoma skin, and brain cancers. However, higher rates of bladder cancer were detected among those with contact allergies.
Companies that use pink ribbons and support breast cancer research but permit the use of carcinogenic chemicals are committing a form of social injustice, argue authors. The practice of pinkwashing increases profits while potentially contributing to higher cancer rates.
A University of Michigan study found that breast cancer patients may be underreported for radiation treatment after breast-conserving surgery, with discrepancies in the SEER database affecting up to 1 in 5 cases. The study highlights the need for improved data accuracy to inform clinical decision-making and policy.
A new study published in Annals of Internal Medicine finds that massage therapy is more effective than usual medical interventions for improving pain and function in patients with chronic low back pain. The researchers also suggest that relaxation massage may have a slight advantage over structural massage due to its wider availability.
Researchers found clinical and personal barriers hinder mammography screening among African-American women. Interventions can be effective by educating providers to build trust, offer culturally appropriate health education, and make referrals.
A team of researchers at CSHL identified the PTPN23 enzyme as a significant regulator of breast cancer development. Suppressing its expression in human mammary cells led to a cascade of effects, including cell scattering, invasion through extracellular matrix, and metastasis.
A study of 64,034 women found that those with heart problems, chronic lung disease, and diabetes had lower overall survival rates. Researchers conclude that managing both cancer and comorbidities is crucial for improving patient outcomes.
A large-scale Swedish trial shows that regular mammography screening reduces breast cancer mortality by 30% over seven years. The study's findings confirm the long-term benefits of mammography screening and provide new insights into its impact on breast cancer deaths.
A recent study shows that regular breast screening with mammography significantly reduces the number of deaths from breast cancer. Over 130,000 women were monitored for nearly three decades, and results indicate that 30% fewer women in the screening group died of breast cancer.
A study led by St. Jude Children's Research Hospital found that about 10% of adult childhood cancer survivors develop new tumors unrelated to their original cancers. Regular cancer screenings are crucial for this growing population.
A team of researchers has identified a new breast cancer tumor suppressor called Runx3, which regulates gene expression and targets the estrogen receptor alpha. The study found that Runx3 suppressed breast cancer cell growth and inhibited tumor formation in mice, offering potential benefits for early detection and treatment.
A new study from UT MD Anderson Cancer Center found that nearly half of women with advanced breast cancer in the US are not receiving life-saving post-mastectomy radiation therapy (PMRT), despite evidence-based guidelines outlining its benefits. The study suggests that better strategies, such as requiring compliance for accreditation a...
Researchers identified six distinct subtypes of triple-negative breast cancer, each responding differently to chemotherapies. The study provides molecular targets for drug discovery and development efforts, offering hope for personalized therapy.
Research at Yale University reveals 10-20% of breast cancers classified as ER negative are actually positive, leading to under-treatment and missed opportunities for effective therapies. A new method for standardizing Estrogen Receptor measurement has been developed, which detects the receptor with higher sensitivity and reproducibility.
A new study found that despite publication of treatment guidelines, only 55% of older high-risk breast cancer patients received recommended radiation treatment after mastectomy. The lack of improvement in radiation use suggests guidelines may not be effectively improving care for breast cancer patients.
A new breast cancer risk model quantifies the impact of modifiable lifestyle factors on absolute breast cancer risk. The study predicts a 1.6% to 4.1% reduction in absolute risk among women aged 65, with higher reductions seen among those with positive family history or more non-modifiable risk factors.
Research published in BioMed Central's Breast Cancer Research journal found that two-thirds of women with breast cancer died from other causes, with cardiovascular disease being the leading cause of death. Women over 50 with co-existing health conditions were most likely to die from non-cancer related causes.
The American Cancer Society's latest report finds a steady decline in overall cancer death rates since the early 1990s, with about 898,000 deaths avoided between 1990 and 2007. However, progress has not benefited all segments of the population equally, with cancer death rates among less-educated individuals being more than twice those ...
A new roadmap has been published to understand estrogen signaling in breast cancer cells, which could lead to better treatments and therapies. The model aims to capture the molecular events controlling cell growth, proliferation, damage responses, and programmed cell death in mathematical form.
A new combination of a breast cancer chemotherapy agent and an artificial antibody has been tested in clinical trials, showing promising results in targeting colon cancer cells. The treatment, which combines lapatinib with monoclonal antibodies, has the potential to provide hope for patients with treatment-resistant cancers.
A study by Rosalia C. M. Simmen found that blueberry powder improved indicators of rat mammary gland health, including branching and biochemical markers like PTEN. The effects have not been shown in humans and may aid breast cancer research.
Research in mice reveals a link between pregnancy and tumor dissemination, with decreased NK cell activity and myeloid-derived suppressor cells contributing to metastasis. The study suggests that these immune cells may represent a shared mechanism of immune suppression during pregnancy and tumor growth.
Researchers found that Bim is required for anti-cancer therapies targeting tumor blood vessels to be effective. The discovery could lead to new treatments by attacking both the tumor and its blood supply.
A new imaging agent called 18F FPPRGD2 targets breast tumor development by detecting angiogenesis, a process that forms new blood vessels in tissues. This allows for better clinical decisions and earlier identification of patients who are ideal candidates for aggressive therapies.
Researchers from NYU Cancer Institute presented studies on the association between MC1R variants, ultraviolet light exposure, and melanoma risk. They also identified serum-based microRNAs as biomarkers for melanoma recurrence. These findings suggest that naturally occurring genetic variations in MC1R may increase an individual's predis...
A study found that gamma imaging outperformed ultrasound in detecting breast cancer, especially in women with dense breast tissue. Gamma imaging provided 100% sensitivity and 82% specificity, leading to a better prognosis for breast cancer patients.
Researchers found that myeloid-derived suppressor cells mediate immune suppression during pregnancy, allowing tumors to spread more easily. This mechanism may also be relevant to lung cancer patients with poor prognosis.
A hormone test measuring anti-Mullerian hormone (AMH) levels can predict a woman's ovarian function after chemotherapy for breast cancer. Women with low AMH levels before treatment are more likely to experience infertility due to chemotherapy-induced damage.
A Mayo Clinic study found that flaxseed does not significantly reduce hot flashes in breast cancer patients and postmenopausal women. The researchers suggest alternative uses for flaxseed, such as managing constipation.
Women with obesity before and after diagnosis have a higher risk of dying from breast cancer. Obesity is strongly linked to death due to breast cancer, particularly in estrogen receptor-positive cases.
Researchers identified phytochemicals in mushrooms that block aromatase enzyme activity, potentially reducing estrogen levels and killing hormone-dependent breast cancers. Early-stage studies show promise in preventing breast cancer recurrence and treating lung cancer.
University at Buffalo researchers and hundreds of Western New York women participated in a phase III clinical trial evaluating exemestane, which reduces breast cancer risk by 65% in postmenopausal women at increased risk. The study found no serious toxicities and minimal changes in quality of life.
A new study found that adding radiation therapy to breast-conserving surgery improves disease-free survival and reduces cancer recurrence in women with early breast cancer. The treatment significantly lowered the rate of recurrences in the breast and lymph nodes, as well as in other parts of the body.
Women with early-stage hormone receptor-sensitive breast cancer who received zoledronic acid alongside standard hormone therapy had a significantly lower risk of cancer returning (32%) compared to those on hormone therapy alone. The treatment's anticancer benefit persisted even after stopping treatment for over two years.
Researchers found that the HSPPC-96 vaccine for recurrent glioblastoma (GBM) extended median survival to 11 months, compared to the current three to five month survival rate. The vaccine showed a favorable safety profile and evoked a significant innate immune response in patients.
A large study by Mayo Clinic and NCCTG found that PTEN status has no significant impact on disease-free survival when Herceptin is added to chemotherapy. Patients with HER2-positive breast cancer did equally well regardless of PTEN activity levels.
Researchers are testing a new treatment for triple-negative breast cancer using the experimental drug entinostat, which aims to reprogram tumor cells to respond to hormone therapy. The clinical trial is evaluating the effectiveness of combining entinostat with an aromatase inhibitor in postmenopausal patients.
Researchers are conducting a clinical trial called MANTICORE to detect and treat cardiovascular disease in breast cancer patients before treatment begins. The study aims to use special blood tests and imaging scans to identify potential cardiac risk factors.
Researchers found that increasing CRP levels resulted in increasingly poor prognosis, with a five-year survival rate decreasing from 90% to 74% and deaths from breast cancer increasing from 11% to 20%. Elevated CRP at diagnosis remained predictive of overall survival rates even after excluding patients with suspected bacterial infections.
Researchers identified a key role for hedgehog in breast cancer cellular cross-talk, finding that silencing the molecule slows tumour growth and spread. The discovery applies to all breast cancers, particularly basal breast cancer, which has no current targeted therapy.
Researchers found that women with estrogen receptor negative cancers who did not receive radiation were 91% more likely to die from breast cancer. There is a corresponding increase in the use of radioactive implants for these patients.
New research finds that women with BRCA1/2 mutations who undergo prophylactic oophorectomy and take short-term HRT have a decreased risk of developing breast cancer. However, the procedure also increases the risk of early menopause and related quality-of-life issues.